MX2024004878A - Composiciones y métodos para el tratamiento de la lesión escamosa intraepitelial de alto grado (hsil) anal. - Google Patents

Composiciones y métodos para el tratamiento de la lesión escamosa intraepitelial de alto grado (hsil) anal.

Info

Publication number
MX2024004878A
MX2024004878A MX2024004878A MX2024004878A MX2024004878A MX 2024004878 A MX2024004878 A MX 2024004878A MX 2024004878 A MX2024004878 A MX 2024004878A MX 2024004878 A MX2024004878 A MX 2024004878A MX 2024004878 A MX2024004878 A MX 2024004878A
Authority
MX
Mexico
Prior art keywords
methods
squamous intraepithelial
grade squamous
intraepithelial lesion
hsil
Prior art date
Application number
MX2024004878A
Other languages
English (en)
Spanish (es)
Inventor
Jian Yan
Jeffrey Skolnik
Jong Joseph Kim
Prakash Bhuyan
Original Assignee
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inovio Pharmaceuticals Inc filed Critical Inovio Pharmaceuticals Inc
Publication of MX2024004878A publication Critical patent/MX2024004878A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024004878A 2021-10-22 2022-10-21 Composiciones y métodos para el tratamiento de la lesión escamosa intraepitelial de alto grado (hsil) anal. MX2024004878A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163270929P 2021-10-22 2021-10-22
PCT/US2022/078551 WO2023070109A1 (en) 2021-10-22 2022-10-21 Compositions and methods for treating anal high-grade squamous intraepithelial lesion (hsil)

Publications (1)

Publication Number Publication Date
MX2024004878A true MX2024004878A (es) 2024-07-15

Family

ID=86059748

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004878A MX2024004878A (es) 2021-10-22 2022-10-21 Composiciones y métodos para el tratamiento de la lesión escamosa intraepitelial de alto grado (hsil) anal.

Country Status (10)

Country Link
US (1) US20230233659A1 (enExample)
EP (1) EP4419138A4 (enExample)
JP (1) JP2024539188A (enExample)
KR (1) KR20240099266A (enExample)
CN (1) CN118382457A (enExample)
AU (1) AU2022371672A1 (enExample)
CA (1) CA3235779A1 (enExample)
CO (1) CO2024006161A2 (enExample)
MX (1) MX2024004878A (enExample)
WO (1) WO2023070109A1 (enExample)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3421046A1 (en) * 2014-11-04 2019-01-02 Janssen Vaccines & Prevention B.V. Therapeutic hpv16 vaccines
HK1252967A1 (zh) * 2015-08-20 2019-06-06 Janssen Vaccines & Prevention B.V. 治疗性hpv18疫苗
KR20250008956A (ko) * 2017-05-11 2025-01-16 이노비오 파마수티컬즈, 인크. 면역요법 후 고등급 자궁경부 이형성증의 회귀 및 hpv16 및 hpv18 감염의 클리어런스를 위한 임상적 및 면역학적 바이오마커
US20230277645A1 (en) * 2020-04-02 2023-09-07 Inovio Pharmaceuticals, Inc. Compositions and methods for treating vulvar dysplasia

Also Published As

Publication number Publication date
CO2024006161A2 (es) 2024-06-27
KR20240099266A (ko) 2024-06-28
JP2024539188A (ja) 2024-10-28
WO2023070109A1 (en) 2023-04-27
US20230233659A1 (en) 2023-07-27
CN118382457A (zh) 2024-07-23
EP4419138A1 (en) 2024-08-28
CA3235779A1 (en) 2023-04-27
EP4419138A4 (en) 2026-03-04
AU2022371672A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
MX2026002469A (es) Nuevas moleculas de acido nucleico artificiales
MY209319A (en) Compounds useful to treat influenza virus infections
SA522441314B1 (ar) لقاحات لوُرام حليمي تنفسي متكرر وطرق استخدامها
WO2020047161A3 (en) Engineered immunostimulatory bacterial strains and uses thereof
MX2020004994A (es) Inhibidores de acss2 y metodos de uso de los mismos.
MX2023007319A (es) Vacunas de acido nucleico.
MX2011007692A (es) Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion.
MX2022002211A (es) Composiciones y metodos para tratar infecciones virales.
BR112016026721A2 (pt) vacinas com base em vesículas do tipo vírus (vlvs) para prevenir ou tratar infecção por vírus da hepatite b (hbv) crônica
MX2020009262A (es) Vectores de parapoxvirus.
EA201990717A1 (ru) Новая вакцина против гриппа свиней
MX2019004029A (es) Compuestos y metodos para diagnosis y tratamiento de infecciones virales.
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
MX2017002081A (es) Metodo para tratar cancer de cuello uterino.
EP4364805A3 (en) Novel pyridazines
WO2021202949A3 (en) Compositions and methods for treating vulvar dysplasia
Ellerhoff et al. Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus
MX2025000120A (es) Vaccinia virus oncoliticos y virus recombinantes y metodos de uso de los mismos
WO2021081480A3 (en) Improved vaccines for recurrent respiratory papillomatosis and methods for using the same
PH12017501165A1 (en) Dengue virus vaccine compositions and methods of use thereof
PH12017501100B1 (en) Recombinant swinepox virus and vaccines
BR112022019334A2 (pt) Método para produzir um genoma viral interferente defeituoso, genomas virais interferentes defeituosos, partícula interferente defeituosa, método de tratamento de uma infecção viral, genoma interferente defeituoso, composição farmacêutica, imunogênica ou terapêutica, vacina, uso, polinucleotídeo, vetor de expressão ou plasmídeo e linhagem de células
WO2021158755A3 (en) Leptospiral proteins and uses thereof
JP2025188115A (ja) 新規遺伝子組換えワクシニアウイルス及びその利用
MX2014004537A (es) Vacunas para el virus del papiloma humano y metodos para su uso.